Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Sweden
Finland
Denmark
Norway
Latest
Trending
Followed

Surgical Science Sweden, Audiocast with teleconference, Q1'24

By Inderes5/15/2024, 9:00 AM
Surgical Science Sweden

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Gisli Hennermark
00:00 - 10:24

Good day. My name is Gisli Hennermark. I'm the CEO of Surgical Science, and I also have our CFO on board with me. I will start off this presentation with some general comments on our first quarter in 2024, and a bit about how we see the rest of the year. And then I will provide some details afterward. We will have time to address any questions you may have. So educational products started the year really weakly and nosedived. Sounds perhaps a bit harsh, but that's what it feels like when your revenue decreases by 45% quarter over quarter from last year compared to this year; we are experiencing customers that are a bit anxious after last year's experiences or budgets that didn't work out, criticism that they were running a deficit. Now they have fresh budgets, but they kept a tight grip on their wallets initially. We also see that among our markets, the United States performed rather well, which is a direct sales market. But the big delta was in our distributor markets, where we sell our products, our educational products, through partners, through distributors, and looking at the delta. And with the delta, I mean the difference between 2023 and 2024 for the first quarter; the largest part of the decrease, the delta, was the fact that we did not have any large tenders in Q1 this year. Usually, every quarter we have some multi-simulator, large tenders, which is a really strong part for us, Surgical Science, as we have such a broad product portfolio. This year, the year didn't start with any. And last year, we had three: one in Europe. In Poland specifically, there was a large one; we had one in Asia and we had one in Latin America. Another factor was the backlog. The comparable included 17 million Swedish crowns. That was sales that were made at the end of 2022, but delivered at the beginning of 2023. And we did not have this effect this year. And we previously disclosed that effect. Then China, the delta was 12 million. It doesn't mean that we didn't sell simulators to China this year in Q1, just as we did last year in Q1. But we sold for 12 million less than last year. And really, the market keeps on being a bit frozen in China. And it's related to the anti-corruption initiative by the government specifically targeting healthcare and teaching institutions. China is always a bit hard to predict, but we believe that this effect will ease up during the year. And finally, there was an 8 million Swedish crown difference in India. And that is a completely frozen market right now because they're holding elections and then it's illegal for government purchases. But we do see the demand. We do see the need. We have a really good visibility on our pipeline. And we recently had our annual sales meeting where we met all of our partners. We go through the pipeline, we know what's coming, and it does look good for the year. And if we summarize it, I can say that Q2 will be better than Q1 for educational products and 2024 will have growth. So we expect educational products to come back during the year and end up on a positive note. If we then move on and we look at the really positive part of our report, it was the Industry/OEM that grew very strongly and actually our simulator sales, when we sell both hardware and software with customized simulators for specific product training, those revenues grew by 300%. They actually ended up at the all-time high of 35 million Swedish crowns. So we're very pleased to see this. And I am personally very pleased to see how we're able to combine different products and different technologies in our broad portfolio and our broad competence to deliver solutions to these customers. And we have built up a healthy backlog there. And we see this trend continuing with strong growth throughout the year. And if we then move on to license revenues where we are compensated by our surgical robotics customers for utilizing our software that's embedded in their robots. It started the year with 63 million. So it's a slight decrease. 7 million. Actually back at what was the all-time high in 2022, the fourth quarter. And this bumpiness is something that we are expecting and it's specifically tied to new entrants who buy their licenses in bundles. So it's not directly tied 1 to 1 when they have their sales. We are noting that Intuitive has disclosed more about the Da Vinci 5 rollout plan, and what they've said is that it will be a very controlled rollout with 2024 focus on existing customers that have been part of the clinical trials and doing more research after the FDA clearance, and next year, increasing supply and also a broader rollout. We're extremely excited about this because this is a big step in surgical robotics when Intuitive comes out with a new platform that has added functionality such as haptics, and it increases our chances of implementing more technology and more simulation that can bring customer value. We also note that there is what could be a sort of a consolidation within the robotic-assisted surgery segment. Recently, Storz announced that they've entered into a non-binding agreement to acquire Accensus Surgical Essentials, as a customer of ours, and we believe this trend will be positive for Surgical Science if it is a trend. It's early days because as large med device companies are entering into surgical robotics, they will add significant financial muscle. But perhaps more importantly, they will add sales channels and sales organizations and customer service and support. That means more customers will be exposed to the technology and can access it, and volumes go up and we receive more license revenue. I have traveled extensively during the spring, and one of the highlights was that I visited SAGES, which is a yearly conference in the United States for the association with the same name. And there was a magnificent ten-year anniversary celebration of the FES program. The FES program is what's called Fundamentals of Endoscopic Surgery. This is a long collaboration that we've had with SAGES, where over 13,000 surgeons have been certified on our simulators for endoscopic maneuverability. And it's just a beautiful thing when you see what that adds to patient safety. And for us as a company, it's also really important to remember that when we work with these end users, we work with academia, and we're closely embedded with medical associations. We gain so much knowledge that we can combine together with our technology to deliver solutions for our med device customers. So that's sort of the core foundation of our strategy. And this is the reason why industrial OEM can grow like it did this year. And for those of you who read our quarterly reports carefully and listen to what we communicate, we actually said last year that our sales strategy for industrial OEM is working, the key accounts strategy, and the people we've hired to work and meet our large med device customers globally is starting to generate results, and we're expecting to see sales in the coming quarters. That's what we said, and that's what happened. And we see this trend continuing for 2024. So after a bit of a rough start, uh, for educational products, we're optimistic and we're confident for the full year. And we see a really strong trend in industrial wear. And with that, I will hand over to Anna for some further details.

Anna Ahlberg
10:26 - 19:47

Yes. Thank you. Continuing a bit on the revenue side on this slide, you see the split in percentage between the two business areas. And the summary for Q1 is, as you've heard, that educational products was weak, having a notch in the curve, while industrial OEM had really strong development. And in total, we had sales of 188 million. That was down 18%, both in Swedish crowns as well as in local currencies. As you know, we are heavily dependent on, above all, the US dollar, where we have more than 80% of our sales and we've had some positive effects from the dollar strengthening, uh, for the past years. However, as you see now, this quarter, it's even between Swedish crowns and local currencies. So we had record sales within industrial OEM, the highest revenues we've ever had, both for the business area as a whole and for simulator sales within the area. And as we said, we had a very focused strategy since one and a half years back, um, which is now starting to pay off. However, educational products declined more than industrial OEM grew. We had very tough comps, but we also saw several distributor markets being weak, such as China. Then we talked about the anti-corruption campaign for quite a few quarters now. India now being frozen, uh, awaiting a new administration and several markets in Europe. But we didn't see any tenders closing. One market that did exceed last year's numbers was the U.S. On the other side, if we look at our revenue streams, we see for the license revenues that they are a bit lower in absolute numbers for this quarter compared to Q1 2023, but at a good level. And being a larger part of our total revenues, 34% compared to 31% in Q1 2023. Again, emphasizing what we also said, that these revenues are a bit bumpy between the quarters since the new entrants purchase the licenses in batches. And we also have a certain seasonality effect also on the subscription side. Simulator sales being 8% of our total sales for the quarter down. In total, approximately 32%. Again, being down more and industry showing very good development at an all-time high. And with that said, we do expect a degree of recovery for educational products in the second quarter. There are a number of major tenders on their way, even though it's always hard to know exactly when they will be completed. Regarding China again, we've said that we expect normalization in the second half of the year at the earliest, and India will still have an effect in Q2, waiting for a new administration. Development revenues were higher. And that is, of course, an effect since simulator sales within the Industry/OEM were higher; they are often tied together in projects where we do adaptations and sell simulators. And these revenues are also, of course, tied to robotic projects. Service revenues continue to be stable and growing with the installed base. New in this report is that we also now divide our regional sales per business area. And you can find that in note two in the interim report. Costs and a bit of the margin for the quarter. We continue to have good cost control. If we look below the gross margin in absolute numbers, all those opex cost lines were below both Q4 and Q1 of last year. On the sales and marketing side, we had two of our largest activities that we have during the year. They were in the first quarter. It's our largest congress. Within Edu Products is the image that was in January this year in San Diego. And we also hosted, as we mentioned, our annual distributor meeting. That was in February this year in Budapest, where we had over 100 of our distributors, people from them in place from more than 40 countries. All in all, sales and marketing costs were 21% of sales. Admin and R&D costs were on par in absolute numbers. If we compare to Q1 2023, 24% of sales and we activated slightly less than 10 million SEK. The line 'Other' was in total slightly negative at -1%. That is costs for our option programs. And it also affects effects on current receivables and liabilities that end up in this line. Going back up a bit. Then to our gross margin, that was 66% for the quarter compared to 69% last year. The increased share of license revenues has a positive effect on the gross margin. However, the product mix was unfavorable, and the fact that we sold fewer simulators also meant that we had higher fixed costs per simulator, also negatively affecting the gross margin. Ebit was then 26 million SEK or 14%. Organization-wise, we increased by five people. During Q1, we were 260 going out of 2023 and then 265 people going out of Q1 and net. We had an increase of three people in the US, one in Sweden, and one in what we call other, which is primarily Germany and China. The adjusted EBIT, where we have our financial goal for the present in 2026, was 17% for the quarter, or 32 million SEK. And the finance net was 2 million SEK. We had a positive of 6 million for interest income, and then a negative for revaluation of internal loans towards subsidiaries, and also the IFRS 16 effect. Net result for the quarter was then 24 million SEK. Looking at our cash flow. Cash flow from our operating activities was plus 28 million. We did have a negative effect on working capital since both inventory and accounts receivables increased somewhat. That was partly offset by the fact that current liabilities also increased somewhat. Cash flow from investing activities for this quarter was primarily investments in development costs and from financing primarily related to IFRS 16. The gray line you see there on the graph is our accounts receivables as a percentage of rolling 12-month sales, which is something we follow closely and have worked hard with, and it remains at a good level. Also, helping the fact that we increased cash by approximately 25 million during the quarter, which we think was good in view of this quarter. And we ended with a cash position of 660 million crowns. With that, we conclude the presentation and can open up for questions.

Operator
19:52 - 20:16

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Simon Johnson from Berenberg. Please go ahead.

Unknown 1
20:17 - 20:48

On Tuesday morning, a couple of questions from me. Uh, the first one is on education. And really, how can you be so confident that we will see growth in 2024? Do you have visibility on larger tenders over the next quarters? It just goes against your comments that customers are holding a tight grip on their wallets. And also related to that. What are you hearing about your customers' budgets for 2024 compared to 2023?

Gisli Hennermark
20:52 - 21:58

All right. Um. So, Simon, the confidence comes from years of analyzing pipeline numbers and knowing all these distributors. Uh, it has been a tough start to the year, and customers are a bit shell-shocked from 2023 when the budgets didn't work out. Uh, so they've been very cautious. But we see the actual deals in the pipeline. And we also note that macroeconomics are again favorable for us. Inflation is coming down. And we are really confident that many of these deals will take place in 2024. And when we add all that up to a big picture, we are confident that Edu Products will grow in 2024.

Unknown 1
22:00 - 22:27

So, to follow up on that, could you maybe help us understand the sequential development a little bit better? How much of this will rely on Q4? I mean, it's the seasonally strongest quarter. And I'm just thinking that. Maybe the budgets are better, but. But they will still likely. Wait for another order until then. Or how should we think about that?

Gisli Hennermark
22:29 - 23:36

Well, it's not like we're not selling anything. Even if a decrease from 140 plus down to 79 is a big decrease. But also, if you look at how we broke down and disclosed a lot of detailed information for everyone to understand that bridge, you also see that there aren't that many factors. I mean, the comparable was tough. There's nothing to do about that. But a lot of it is attributable to large tenders. And we have really good visibility on large tenders. We know there will be a new government in India, even if that is perhaps not the biggest delta. It was 8 million. And we do feel confident that at some point, China will bounce back. We've seen that many times historically, but it's a bit more tricky with China to know exactly when. But all these things combined make us see a strong, solid 2024.

Unknown 1
23:38 - 24:03

All right. Perfect. The second topic is robotics and license revenues. Could you also help us sort of get more color on the 11% decline here year over year? You're mentioning that it's partially because customers are buying licenses and bundles. Is that the main reason, or could you comment on the underlying development if we exclude this effect?

Gisli Hennermark
24:07 - 25:45

There is some inherent bumpiness related to one. Customers, especially new entrants, are buying licenses in bundles too. There is also some bumpiness in when the recurring revenue in terms of subscriptions is renewed. So these two things contribute to some bumpiness. What we see in the market is a brand new robot from Intuitive. We see advances among many other surgical robotics companies. And we are embedded in 15 of these companies with our software. Of course, there are some varying degrees of success as they start to enter the market, get regulatory approval, and so on. There was actually a Chinese customer, a Chinese company that got regulatory approval in Europe just recently. All these factors mean that there is some bumpiness, but we don’t see any difference in the outlook of the strong trend of surgical robotics moving forward, and our role in supporting those customers within that niche. So, we feel confident about the surgical robotics portion of our revenue streams.

Unknown 1
25:47 - 26:05

Okay, and in terms of the da Vinci 5, your comment in the report makes it clear that that will be more of a 2025 story. Do you have any more visibility on how this might affect your license revenues in 2024?

Gisli Hennermark
26:07 - 27:02

Nothing that I can comment on. Of course, we have a very close working relationship with all of our customers, but I note that Intuitive themselves, and that's why I'm quoting them, has talked about a phased, controlled rollout and limited supply throughout the year, with supply increasing in 2025. I also want to comment on the fact that for us as a simulation company, it's really exciting to see all that added functionality. That means that we are in a position to add more meaningful technology to such a platform without making any further comments or drawing any conclusions or disclosing anything about Intuitive’s plans going forward.

Unknown 1
27:05 - 27:07

All right, that was all for me. Thank you so much.

Unknown 2
27:08 - 27:08

Thank you, sir.

Operator
27:22 - 27:28

The next question comes from Christian Li from Perito Securities. Please go ahead.

Unknown 2
27:31 - 27:32

Yes.

Unknown 3
27:32 - 27:47

Good morning, and thank you for taking the questions. The first one is a follow-up on the Da Vinci A5, adding more features. Does this mean more project development opportunities for you in the short term?

Gisli Hennermark
27:49 - 29:18

I really can't comment specifically on one customer. Christian, but on a broader level, the more complex features being added in the technology from surgical robotics companies mean that physicians can do more things with the robots. And for the sake of patient safety, they also need more training. We outgrew the market in an amazing way last year, where our licensed revenue grew by 50%, whereas the market certainly didn't grow by 50%. We have no reason to believe that this trend over time is going to change because customers are also increasingly moving towards simulation, as simulation is advancing and we're able to do things that we couldn't do before, because we are investing in our technology. And also from an ESG perspective, it really doesn't make sense to use living animals or cadavers, meaning deceased humans, for practice. So all this combined makes us really excited about the future.

Unknown 3
29:21 - 29:42

Okay, great. Second question is also regarding da Vinci 5. It seems like the robotic systems will include simulation by default, that the customers previously had to purchase separately. Is this the reason why you expect the license revenues to pick up significantly next year?

Gisli Hennermark
29:45 - 30:30

I can't again, I cannot comment specifically on one customer, I simply can't. I'm not in a position to do that. But if you look at how the robotic-assisted surgery industry is developing, and new players are coming to market and simulation is becoming a de facto standard, everyone expects it to be included on the console. I mean, that's what surgeons, physicians, and other hospital staff are coming to expect. And the supplier of that world-leading simulation is Surgical Science. So, that's a positive for us.

Unknown 3
30:32 - 30:41

Yeah, sure. My final question. Would it be possible to disclose how much of the license revenues are subscription-based?

Anna Ahlberg
30:43 - 31:19

We know that this is something that would be interesting to see. And, as you know, we try every year to add more information to our reports. And this year, it was the geographic split that we have in a more granular way. We have not disclosed the split and we cannot do so yet. That is our judgment from a sensitivity point of view. You know, the only thing we said is when we acquired Bionics that the larger part of their revenues from Intuitive were subscription-based.

Unknown 3
31:22 - 31:24

Okay. That's clear. Thank you very much.

Unknown 2
31:26 - 31:26

Thanks.

Operator
31:28 - 31:47

As a reminder, if you wish to ask a question, please dial Pound Key five on your telephone keypad. The next question comes from Ulrich Ratner from Carnegie. Please go ahead.

Unknown 3
31:50 - 31:53

Great. Thank you very much. And good day.

Unknown 2
31:53 - 31:57

Amanda, a few follow-ups.

Unknown 1
31:57 - 31:58

You're referring to

Unknown 2
31:58 - 32:00

A rather tough

Unknown 3
32:00 - 32:01

Situation in China.

Unknown 1
32:01 - 32:02

Previously, you've

Unknown 2
32:02 - 32:41

Sounded more upbeat. Um, I know it's a tricky one, but if you could help us decipher how. So transparent. Can it be that the market will improve despite a sort of historical pattern? And as well as your reference to India in educational products and the lack of opportunity to capture orders there. Um, but for transparency reasons as well. Can you help us provide some more granularity on what sales were derived out of India for Q2 and for the full year in 2024? That would be my first question.

Gisli Hennermark
32:43 - 34:16

Sure. Um, India is pretty simple. I mean, after they've elected a new government, they will start business as usual again. Uh, and we have a great distributor. They're a great partner. Great visibility on business and tenders and so on. We haven't disclosed absolute numbers for the markets, but the fact that the deviation was 8 million, uh, you know, we really tried to add some transparent data points in order to understand the dip in educational products. Uh, at least it tells you something when it comes to China. Woolrich. Uh, you know, I travel extensively to China. It's a very important market for us, not least in the Industry/OEM sector, where we really see big opportunities and we're strengthening our organization there. We have our own office; we have our own people. Uh, but it's really tricky to know, and we commented in one of the Q reports last year that we saw the Chinese market potentially opening up at the beginning of this year, and it didn't happen. So I will just bite my tongue in terms of exact timing. But we do really know the end users there and the medical community. So we are confident that it will come back. But the exact timing is difficult. We anticipate it to be in the second half of this year. But it is difficult to know with China.

Anna Ahlberg
34:18 - 34:31

And again, just emphasizing that that is on the educational product side. On the Industry/OEM side, we see a lot of activities in China and a lot of positive development.

Unknown 2
34:33 - 35:24

That's fair enough. And you also talked about that you're seeing tenders out of the Edu Products segment. But correct me if I'm wrong, but I interpreted it as you haven't. These have not been finalized too. So you have one and a half months left for Q2 for these tenders to be finalized and for you to deliver products on these. What's your confidence in that as well as if we're talking here at potentially at best flat organic growth for the educational segment for the full year 2024? Do you think that you will need to revise your financial targets on sales and margins as well for 2026? That would be our final question. Thank you.

Gisli Hennermark
35:25 - 36:48

Yeah. No, but what we said earlier is that Q2 would be better than Q1 for educational products, and 2024 will have growth over 2023. When it comes to the tenders, there was one specifically mentioned here. We said that it was a large deal in Poland last year. I mean, this comes from years of work and, you know, EU financing, etc. So I really do feel that we have a good grip on major tenders. Uh, the exact timing, uh, we have not said anything about, but we always, typically, always have large tenders in any quarter. And we haven't said anything specifically about Q2 or if there are large tenders in Q2. But we said that we know that Q2 will be better than Q1 and 2024 as a whole. And when it comes to the 2026 financial goals, there is no change in that. Uh, we are as confident as we were before Q1 of 2024 that we will accomplish our goals by 2026 of 1.5 billion Swedish crowns in revenue and 40% adjusted EBIT margin.

Unknown 2
36:51 - 36:54

Okay. Great. Thanks for taking my question. I'll get back into the Q.

Operator
37:00 - 37:05

The next question comes from Christian Binder from Red Eye. Please go ahead.

Unknown 3
37:09 - 37:09

Hi and thanks so.

Unknown 4
37:09 - 37:32

Much for taking my question. I just have one quick follow-up. You mentioned, um, vascular surgery as a particular area of strength. Um, can you elaborate a little bit on what you're taking market share there and how you see the competitive environment developing? Um, is your position improving relative to competitors there?

Gisli Hennermark
37:34 - 38:51

Thank you, Kristen. Yeah. We noted that, uh, our strong start to the year and what we anticipate to be a strong continuation of the year for simulators, hardware, and software to meet device customers, had a good portion of revenues within vascular surgery. And, uh, that's the competitive market. Uh, I know you follow our competitor Mantis, uh, and we have been winning a lot of business, but, uh, even if we are competitors, uh, sure, we are in direct competition in some tenders, but it's also a little bit of a customer mix. You know, we have some different customers, different strengths. And we're deeply embedded in different customers. Of course, we want to gain market share and win over them. And uh, I can't remember exactly, but I think their start of the year was uh, was a bit weaker in that segment. But, uh, it's more that I feel that we are coming out with our technology and we're able to combine our technology within our different products to deliver really meaningful solutions to the customers.

Unknown 4
38:53 - 38:56

All right. Perfect. That was all for my side. Thank you so much.

Operator
39:07 - 39:15

There are no more questions at this time, so I hand the conference back to the speakers for any written questions and closing comments.

Anna Ahlberg
39:16 - 40:35

So let us look at the written questions. Uh, there is a question around capital allocation and the strategy going forward regarding this and our cash position. Uh, yes. Continues to increase. Um, and what we've said all along is that, I mean, we have the same strategy as we have had over the past years. We do not need a lot of capital for our day-to-day business that is generating cash, meaning that would be for other projects. And as you know, um, acquisitions have been a successful part of our strategy in the past, and it continues to be something that is an important part of our strategy going forward. Um. And so that is still the same. The same answer to that question. Um. Then I see a question. If there were any surprises or missed planning happenings during the quarters.

Gisli Hennermark
40:37 - 42:12

Um, let me see if I can interpret this question. Uh, of course. I mean, it is a big mishap to declare that the revenues decreased in educational products, which is such a significant amount. Uh, and like I said, it felt like it was a nosedive. It felt like a nosedive. And what do you do after that issue? You get up and you look ahead. Now, did we see that happening? Uh, you know, a lot of our deals come late in the quarter, and visibility of the exact timing, If a deal is going to be in March or in April or something like that, it usually happens rather late. So I wouldn't say we expected it, but it was in line with what we communicated. Also in the Q4 report, we do see a healthcare system. And this is the same for all over the world. That is having a tough time. Uh, the inflation that hit them last year and budgets not being met meant that a lot of them had a really tough time. So, uh, holding onto that, they are holding onto the bullets. Uh, initially, maybe we could have figured that out, but we did not know that until it happens, so to speak.

Anna Ahlberg
42:13 - 42:39

And there is a question about the da Vinci 5 that I hope we have answered. We talked a lot about the da Vinci 5. Uh, and then the last written question, there is one about the Gaza conflict. Have we lost orders or market share due to the conflict since? We do have half of our staff in Tel Aviv.

Gisli Hennermark
42:41 - 44:42

And the short answer to that question is no. Um, the somewhat longer answer on the war in Israel, uh, is that it continues to be tough emotionally for our team, for our colleagues, for our friends in Tel Aviv. Um, but we also see that being a Swedish, Israeli, and US company, we are truly a global company. Uh, it's an amazing team spirit. Uh, that just got stronger after the conflict, how people are backing each other up, how we as a very diverse company with all sorts of religions and political opinions are really pulling together as one team. Uh, I also note that if anything, um, with a bit of a downturn in the Israeli economy, it's been easier to attract and retain talent there. So, as you can see in our staffing statistics, we've continued investing in Israel, and we will keep on investing in Israel. It's a great source of competence in that country. And even if we all think that the war is terrible, uh, we will keep our fingers crossed that there will be an end to that. So nothing has changed in that aspect. And. With that. I think we are all done. We don't see any new questions coming into the chat and everyone has had a chance to ask their questions. So with that, I thank you all for listening and uh, hope to interact and see many of you in the coming months and perhaps even some at our AGM, which takes place tomorrow in sunny Gothenburg. Thank you, thank you.

Continue to the webcast
Pierce Group, Audiocast, Q3'26
Language: English11/13/2026, 8:00 AM
Göran Dahlin Good morning, everyone, and welcome to Pierce Group's presentation of our Q3 2026 interim results. Next slide, please. I am Göran Dahlin, CEO of Pierce Group, and I am with Fredrik Kjellg…
Surgical Science Sweden, Audiocast, Q3'26
Language: English11/12/2026, 10:00 AM
Tom Englund Hi everyone, and welcome to this earnings call for Surgical Science for the third quarter of 2026. My name is Tom Englund. I am the CEO. And with me today is our CFO, Anna Ahlberg. I wil…
ExpreS2ion Biotech – Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 9:00 AM
ExpreS2ion is expected to release its Q3 2026 interim report on 12 November 2026. Later the same day at 10.00, ExpreS2ion’s CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.
Meko Services AB, Q3'26
Language: English11/12/2026, 8:00 AM
Pat Thank you. Good morning, and welcome to MEKO's presentation of the third quarter of 2026. I am here with our CFO, Christy Johansson, and I will begin with an overview of the quarter and some of th…
WeSports Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Unknown 1 It. Ted Sporre Welcome to our Q3 release presentation. As you know, we have already shared preliminary figures for sales and EBITDA for this quarter, but today we complete the picture. We wi…
Nordrest Holding, Audiocast, Q3'26
Language: Swedish11/12/2026, 8:00 AM
Thomas Dahlstedt Hej och välkomna! Vi ska idag presentera Nordrests senaste kvartal och tillika resultatet för perioden. Jag som pratar nu heter Thomas Dahlstedt och är grundare och tillika VD för bol…
Karnov Group, Audiocast, Q3'26
Language: English11/12/2026, 8:00 AM
Pontus Bodelsson Welcome, everyone, to Karnov Group's earnings conference, where we will present the outcome of the third quarter of 2026. Please go to slide two. I am Pontus Bodelsson, President and…
Fasadgruppen Group, Audiocast, Q3'26
Language: English11/12/2026, 7:15 AM
Magnus Blomberg Perfect. Good morning and welcome to the Fasadgruppen presentation of our results for the third quarter 2026. My name is Magnus Blomberg. You have met me before. I am the CFO of Fasadg…
Munters AB, CMD
Language: English11/11/2026, 1:00 PM
Lena Dauvergne Good. Good afternoon everyone, and a warm welcome to Stockholm, to ESSEX and to Montage Capital Markets Day 2026. Montage Capital Markets Day 2026. It is really good to see so many of y…
Cinclus Pharma, Audiocast, Q3'26
Language: English11/11/2026, 1:00 PM
Christer Ahlberg Thank you. Hello and welcome to the Cinclus Pharma third quarter 2026 earnings call. I am Christer Ahlberg, CEO of Cinclus Pharma, and with me today is our CFO, Magnus Christensen. We…
Proact IT, CMD
Language: English11/11/2026, 12:30 PM
Unknown 1 The world of data is constantly changing. Breaches are rising, and attacks are getting more advanced. Regulation drives the need for data sovereignty. Data has to be available. Critical busi…
Ferronordic AB, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Henrik Good morning, everyone, and welcome to our presentation of the third quarter of 2026. During the quarter, we saw higher earnings, and growing aftermarket revenue was up 15% to 1.2 billion Swedi…
BICO, Audiocast, Q3'26
Language: English11/11/2026, 9:00 AM
Anders Fogelberg Good morning, everyone, and welcome to BICO's earnings call for the third quarter of 2026. I am Anders Fogelberg, President and CEO of BICO. And joining me today is our Group CFO, Ewa…
Catena Media, Audiocast, Q3'26
Language: English11/10/2026, 5:00 PM
Manuel Stan Good afternoon. Good evening, everyone. Welcome to the Catena Media Q3 Interim Report. I am Manuel Stan and today I'm joined by our Chief Financial Officer, Michael Gerrow. Today we will b…
Ellos Group, Q3'26
Language: English11/10/2026, 8:00 AM
Hans Ohlsson Live. Good morning, everyone, and welcome to the second presentation for Ellos Group as a listed company. We have 45 minutes today for the presentation. And there is a hard stop. After th…
Scandic Hotels Group, Audiocast, Q3'26
Language: English11/10/2026, 8:00 AM
Jens Mathisen Thank you so much, and good morning, everyone, and thank you for joining us for the Q3 presentation. I am Jens Mathisen, CEO of Scandic. And joining me is our CFO, Pierre Carstensen. We…
Svevik Industri, Q3'26
Language: Swedish11/6/2026, 9:00 AM
Johan Hårdén Tack så mycket! Hello and welcome to this hearing regarding the Q3 2026 interim report. We have an agenda where we intend to introduce ourselves to all the new shareholders as well. Kort…
Attendo, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Martin Tivéus Good morning, everyone, and thank you for joining us. Today, we will present our results for the third quarter of 2026. I am pleased to announce that this is the strongest quarter for At…
Cavotec, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
David Pagels Good morning and welcome to Cavotec's Q3 2026 presentation. I am David Pagels, the CEO of Cavotec. And together with me today, I have our new CFO, Christoffer Robertsson. I would like to…
Fractal Gaming Group, Audiocast, Q3'26
Language: English11/6/2026, 9:00 AM
Jonas Good morning, everyone, and welcome to Fractal's Q3 2026 presentation. Today, we'll take you through our results, the progress that we've made, and our priorities ahead after a difficult first h…